Cysteine-containing protein modifier; Inhibits growth of triple-negative breast cancer cells
CAS
160003-66-7
Synonyme
Iniparib; IND 71677
Quantité
50 mg
Formule moléculaire
C7H5IN2O3
Pureté
≥98%
Marque
STEMCELL Technologies
Caractéristiques principales
BSI-201, also known as iniparib, can interact with the zinc finger domain of poly(ADP-ribose) polymerase 1 (PARP1) in vitro, but fails to inhibit the enzyme (Patel et al.) The nitroso metabolite of BSI-201 is highly reactive and forms non-specific covalent interactions with many cysteine-containing proteins (Liu et al.) BSI-201 has demonstrated anti-proliferative effects in triple-negative breast cancer cells (Chuang et al.; Yin et al.), and early studies indicated that it may be useful in treating early-stage triple-negative and BRCA1/2 mutation-associated breast cancer (O'Shaughnessy et al. 2009); however, its efficacy was later found to be insignificant (O'Shaughnessy et al.) 2014)
